Silexion Therapeutics Corp Announces Reverse Share Split and Warrant Adjustments

Silexion Therapeutics Corp has announced a 1-for-15 reverse share split of its ordinary shares, effective after the close of trading on July 28, 2025. The reverse share split was approved by the company's shareholders at the 2025 Annual General Meeting held on July 14, 2025. As a result of the reverse share split, the number of issued and outstanding ordinary shares has decreased at a ratio of 1-for-15, and the par value of the ordinary shares has increased from $0.0009 per share to $0.0135 per share. The company's ordinary shares will begin trading on a reverse share split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol 'SLXN' at the market open on July 29, 2025. Additionally, the company has adjusted its warrants to purchase ordinary shares, with the number of ordinary shares issuable upon the exercise of each warrant decreasing proportionately to the reverse share split ratio, and the exercise price of each warrant increasing proportionately to $1,552.50 per post-reverse share split ordinary share. The company will not issue fractional shares upon exercise of warrants, and any fractional shares will be rounded up to the nearest whole number of ordinary shares.